Epidemiology of MDR-TB in a belgian infectious diseases unit: A 15 years review

Acta Clinica Belgica

Volumn 68, Issue 5, 2013, Pages 321-324

  Van Heurck, R ^a   Payen, M C ^a   De Wit, S ^a   Clumeck, N ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Pulmonary infectious disease; Surveillance; Transmigration; Tuberculosis control

Indexed keywords

CLAVULANIC ACID; LINEZOLID; MEROPENEM; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; REVIEW; AGED; ARTICLE; BELGIUM; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTITUBERCULAR AGENTS; BELGIUM; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901499703     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.3269     Document Type: Review

References (19)

1. World Health Organisation. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394.Geneva, Switzerland.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland.
3. Van Deun A, et al. Diagnosis of drug resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14(2): 131-140.
4. Chiang C-Y, et al. Management of drug resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14(6): 672-682.
5. Caminero J, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
6. Falzon D, et al. WHO guidelines for the programmatic management of drug resistant tuberculosis: 2011 update. Eur Repir J 2011; 38: 516-528.
7. Krüüner A, et al. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with mycobacterium tuberculosis. Clin Inf Dis 2002; 35: 146-155.
8. Andrews J, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in ruralSouth Africa. J Inf Dis 2008; 198: 1582-1589.
9. World Health Organisation. Multidrug and extensively drug-resistant TB (M/ XDR): 2010 globalreport on surveillance and report, WHO/HTM/TB/2010. Geneva, Switzerland.
10. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14(4): 383-390.
11. Sarita S, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2004; 13: 380-387.
12. Gandhi N, et al. Multidrug-resistant and extensively drug resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 357: 1830-1843.
13. Dye, C. (2009), Drug resistant tuberculosis: biology, epidemiology and control, in Gillespie, S. (ed.), Antibiotic Resistance: From genes to global prevalence, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio).
14. Anger H, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York city 2000-2006, J Antimicrob Chemother 2010 65(4): 775-783.
15. World Health Organisation. The global plan to stop TB 2011-2015, Geneva, Switzerland.
16. Jacobson K, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta analysis. Clin Inf Dis 2010; 51(1): 6-14.
17. Hugonnet J, et al. Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium Tuberculosis. Science 2009; 323: 1215-1218.
18. Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/ Clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Ped Inf Dis J 2011; 30(9): 812-813.
19. Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. The Int Journal of Tuberc and Lung Dis. 2012 16(4): 558-560.